Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence

Nature Cell Biology

Volumn 8, Issue 8, 2006, Pages 878-884

  Kortlever, Roderik M ^a   Higgins, Paul J ^b   Bernards, René ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLIN D1; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN P53; CDKN2A PROTEIN, MOUSE; CISPLATIN; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1A; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P14ARF; PROTEIN P16INK4A;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOWNSTREAM PROCESSING; EMBRYO; ENZYME ACTIVATION; FIBROBLAST; GENE REPRESSION; GENETIC CODE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN TARGETING; RNA INTERFERENCE; RNA REPLICATION; SENESCENCE; ANIMAL; CELL AGING; CELL CULTURE; CELL STRAIN 3T3; CYTOLOGY; DNA DAMAGE; DRUG EFFECT; FLUORESCENCE MICROSCOPY; GENETICS; METABOLISM; MUTATION; PHYSIOLOGY; WESTERN BLOTTING;

MURINAE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; BLOTTING, WESTERN; CELL AGING; CELL PROLIFERATION; CELLS, CULTURED; CISPLATIN; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA DAMAGE; EMBRYO; FIBROBLASTS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MICE; MICROSCOPY, FLUORESCENCE; MUTATION; NIH 3T3 CELLS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33746616991     PISSN: 14657392     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncb1448     Document Type: Article

References (41)

1. Lundberg, A. S., Hahn, W. C., Gupta, P. & Weinberg, R. A. Genes involved in senescence and immortalization. Curr. Opin. Cell Biol. 12, 705-709 (2000).
2. Sherr, C. J. & McCormick, F. The RB and p53 pathways in cancer. Cancer Cell 2, 103-112 (2002).
3. Massague, J. G1 cell-cycle control and cancer. Nature 432, 298-306 (2004).
4. Pantoja, C. & Serrano, M. Murine fibroblasts lacking p21 undergo senescence and are resistant to transformation by oncogenic Ras. Oncogene 18, 4974-4982 (1999).
5. Kunz, C., Pebler, S., Otte, J. & von der Ahe, D. Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53. Nucleic Acids Res. 23, 3710-3717 (1995).
6. Zhao, R. et al. Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev. 14, 981-993 (2000).
7. Mu, X. C. & Higgins, P. J. Differential growth state-dependent regulation of plasminogen activator inhibitor type-1 expression in senescent IMR-90 human diploid fibroblasts. J. Cell Physiol. 165, 647-657 (1995).
8. Martens, J. W. et al. Aging of stromal-derived human breast fibroblasts might contribute to breast cancer progression. Thromb. Haemost. 89, 393-404 (2003).
9. Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D. & Lowe, S. W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593-602 (1997).
10. De Petro, G., Copeta, A. & Barlati, S. Urokinase-type and tissue-type plasminogen activators as growth factors of human fibroblasts. Exp. Cell Res. 213, 286-294 (1994).
11. Brummelkamp, T. R., Bernards, R. & Agami, R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2, 243-247 (2002).
12. Andreasen, P. A., Egelund, R. & Petersen, H. H. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol. Life Sci. 57, 25-40 (2000).
13. Choong, P. F. & Nadesapillai, A. P. Urokinase plasminogen activator system: A multifunctional role in tumor progression and metastasis. Clin. Orthop. 415, S46-S58 (2003).
14. Quelle, D. E. et al. Cloning and characterization of murine p16INK4a and p15INK4b genes. Oncogene 11, 635-645 (1995).
15. Linardopoulos, S. et al. Deletion and altered regulation of p16INK4a and p15INK4b in undifferentiated mouse skin tumors. Cancer Res. 55, 5168-5172 (1995).
16. Sherr, C. J. Tumor surveillance via the ARF-p53 pathway. Genes Dev. 12, 2984-2991 (1998).
17. Cross, D. A., Alessi, D. R., Cohen, P., Andjelkovich, M. & Hemmings, B. A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378, 785-789 (1995).
18. Vivanco, I. & Sawyers, C. L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nature Rev. Cancer 2, 489-501 (2002).
19. Diehl, J. A., Cheng, M., Roussel, M. F. & Sherr, C. J. Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 12, 3499-3511 (1998).
20. Chandrasekar, N. et al. Downregulation of uPA inhibits migration and PI3k/Akt signaling in glioblastoma cells. Oncogene 22, 392-400 (2003).
21. Dimri, G. P. et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl Acad. Sci. USA 92, 9363-9367 (1995).
22. Parsons, R. Human cancer, PTEN and the PI-3 kinase pathway. Semin. Cell Dev. Biol. 15, 171-176 (2004).
23. Radu, A., Neubauer, V., Akagi, T., Hanafusa, H. & Georgescu, M. M. PTEN induces cell cycle arrest by decreasing the level and nuclear localization of cyclin D1. Mol. Cell Biol. 23, 6139-6149 (2003).
24. Dannenberg, J. H., van Rossum, A., Schuijff, L. & te Riele, H. Ablation of the retinoblastoma gene family deregulates G(1) control causing immortalization and increased cell turnover under growth-restricting conditions. Genes Dev. 14, 3051-3064 (2000).
25. Sage, J. et al. Targeted disruption of the three Rb-related genes leads to loss of G(1) control and immortalization. Genes Dev. 14, 3037-3050 (2000).
26. Rowland, B. D. et al. E2F transcriptional repressor complexes are critical downstream targets of p19(ARF)/p53-induced proliferative arrest. Cancer Cell 2, 55-65 (2002).
27. West, M. D., Shay, J. W., Wright, W. E. & Linskens, M. H. Altered expression of plasminogen activator and plasminogen activator inhibitor during cellular senescence. Exp. Gerontol. 31, 175-193 (1996).
28. Brown, J. P., Wei, W. & Sedivy, J. M. Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts. Science 277, 831-834 (1997).
29. Berns, K. et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 428, 431-437 (2004).
30. Chen, Z. et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436, 725-730 (2005).
31. Tuveson, D. A. et al. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 5, 375-387 (2004).
32. Prendergast, G. C., Diamond, L. E., Dahl, D. & Cole, M. D. The c-myc-regulated gene mrl encodes plasminogen activator inhibitor 1. Mol. Cell Biol. 10, 1265-1269 (1990).
33. Parfyonova, Y. V., Plekhanova, O. S. & Tkachuk, V. A. Plasminogen activators in vascular remodeling and angiogenesis. Biochemistry (Mosc) 67, 119-134 (2002).
34. Bissell, M. J. et al. Tissue structure, nuclear organization and gene expression in normal and malignant breast. Cancer Res. 59, S1757-S1763 (1999).
35. Usher, P. A. et al. Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue. Int. J. Cancer 113, 870-880 (2005).
36. Frandsen, T. L. et al. Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) in the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft model. Cancer Res. 61, 532-537 (2001).
37. Almholt, K. et al. Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice. Int. J. Cancer 113, 525-532 (2005).
38. Tuxhorn, J. A., Ayala, G. E. & Rowley, D. R. Reactive stroma in prostate cancer progression. J. Urol. 166, 2472-2483 (2001).
39. Mueller, M. M. & Fusenig, N. E. Friends or foes - bipolar effects of the tumour stroma in cancer. Nature Rev. Cancer 4, 839-849 (2004).
40. Dirac, A. M. & Bernards, R. Reversal of senescence in mouse fibroblasts through lentiviral suppression of p53. J. Biol. Chem. 278, 11731-11734 (2003).
41. Yu, J. Y., Taylor, J., DeRuiter, S. L., Vojtek, A. B. & Turner, D. L. Simultaneous inhibition of GSK3α and GSK3β using hairpin siRNA expression vectors. Mol. Ther. 7, 228-236 (2003).